Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB028 [CNF-3647] Administered to Subjects With Advanced Solid Tumors.

Next Previous
Trial Profile

A Phase 1, Multicenter, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB028 [CNF-3647] Administered to Subjects With Advanced Solid Tumors.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIIB 028 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Biogen

Most Recent Events

  • 08 Dec 2011 Actual patient number is 43 as reported by ClinicalTrials.gov.
  • 15 Sep 2011 Planned End Date changed from 1 Oct 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
  • 17 Mar 2011 Planned end date changed from 1 Aug 2010 to 1 Oct 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top